UEG's content platform for gastroenterology education bringing recordings, courses, guidelines, and more together in one place.

UEG Week Berlin 2025 Recordings Gut Guide online What's new on Gutflix

Trending on Gutflix

Rate for better recommendations!

Your feedback helps us show you more of what you like and less of what you dislike!

More of this!

We will show you more similar content.

Not for me!

We won't suggest this again.

Bookmark!

Save this content for later!

New to myUEG? Create an account! Log In with myUEG account

UEG Poster

Standard Poster

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

ASSOCIATION OF CONTROLLED ATTENUATION PARAMETER AND LIVER STIFFNESS WITH CHRONIC KIDNEY DISEASE IN PATIENTS WITH DIABETES MELLITUS

Hannah Lee 1, Oh Sang Kwon 1, Seung Kak Shin 1, Kiyoung Lee 1, Young Sil Eom 1, Byung-Joon Kim 1, Yun Soo Kim 1, Ju Hyun Kim 1

Affiliations

1 Gachon University Gil Medical Center, Incheon, Korea, Republic of

Summary

AI Generated

In 324 patients with diabetes mellitus, hepatic steatosis measured by controlled attenuation parameter and fibrosis measured by liver stiffness were not associated with chronic kidney disease risk, while age and hypertension were independent risk factors.

Among 324 diabetic patients enrolled between January and August 2023, 8.9% had chronic kidney disease defined as eGFR less than 60 mL/min/1.73m²
Steatosis markers including CAP (273±55 vs. 276±50 dB/m), fatty liver index, and hepatic steatosis index showed no significant differences between patients with and without CKD
Fibrosis markers including liver stiffness (7.0±2.2 vs. 7.0±3.8 kPa), FIB-4, and NAFLD fibrosis score were not different between CKD and non-CKD groups
Multivariate analysis identified age (OR 1.047, 95% CI 1.008-1.088) and hypertension (OR 3.260, 95% CI 1.274-8.339) as independent risk factors for CKD in this diabetic population
This cross-sectional study may be relevant to clinicians managing diabetic patients with suspected NAFLD who are assessing CKD risk

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Introduction

Patients with nonalcoholic fatty liver disease (NAFLD) have a higher risk of chronic kidney disease (CKD).

Aims & Methods

This study aimed to investigate whether the degree of steatosis and fibrosis is associated with an increased risk of CKD in patients with diabetes mellitus (DM). Between January and August 2023, 324 patients with DM were enrolled in the study, after excluding those with viral hepatitis, cirrhosis, and any cancers. Patients provided written informed consent, underwent several clinical measurements, and provided past medical histories. Body weight (BW), body mass index (BMI), waist circumference (WC), laboratory variables including serum creatinine and estimated glomerular filtration rate {eGFR, 175 × Serum Cr^-1.154× age^-0.203 × 1.212 (if patient is black) × 0.742 (if female)}, presence of hypertension, and dyslipidemia were investigated. The degree of steatosis was estimated using the fatty liver index {FLI, (e^{(0.953×ln(triglyceride, TG)+0.139×BMI+0.718×ln(gamma-glutamyltrasnsferase, GGT)+0.053×WC-15.745)})/(1+ e^{(0.953×ln(TG)+0.139×BMI+0.718×ln(GGT)+0.053×WC-15.745)})×100}, hepatic steatosis index {HSI, 8x(alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ratio+BMI (+2, if female; +2, if diabetes mellitus)}, and controlled attenuation parameter (CAP by FibroScan^®). The degree of fibrosis was estimated using fibrosis-4 (FIB-4) index, NAFLD fibrosis score (NFS), and liver stiffness (LS by FibroScan^®). CKD was defined as eGFR less than 60 mL/min/1.73m².

Results

The mean age of the patients was 57±12 years, and 54.9% (n=178) were male. The mean CAP and LS values were 276±50 dB/m and 7.0±3.7 kPa, respectively. CAP values were correlated with BW (r=0.524, p<0.001), BMI (r=0.625, p<0.001), WC (r=0.592, p<0.001), FLI (r=0.637, p<0.001), and HSI (r=0.653, p<0.001). LS values were correlated with BW (r=0.364, p<0.001), BMI (r=0.531, p<0.001), WC (r=0.46, p<001), and FIB-4 (r=0.3, p<0.001), but not correlated with NFS. Twenty-nine (8.9%) patients had CKD, of whom 14 were male. Patients with CKD were older (mean age: 63±11 vs. 56±12 years, p=0.005) and had a higher prevalence of hypertension (79.3% vs. 49.8%, p=0.002) compared to those without CKD. AST (29±22 vs. 30±20 IU/L), ALT (36±39 vs. 37±27 IU/L), GGT (40±30 vs. 44±73 IU/L), and HbA₁C (7.3±1.3 vs. 7.3±1.4%) were not different between the two groups. The prevalence of dyslipidemia (75.9% vs. 63.4%), BW (73±15 vs. 72±15 kg), BMI (28±4 vs. 27±5 kg/m²), and WC (92±11 vs. 90±11 cm) were also not different between the two groups. CAP value (273±55 vs. 276±50 dB/m), FLI (49±29 vs. 48±29), and HSI (40±7 vs. 39±7) were not different between the two groups. LS value (7.0±2.2 vs. 7.0±3.8 kPa), NFS (-1.0±1.3 vs. -1.2±2.6), and FIB-4 (1.3±0.6 vs. 1.2±0.8) were also not different between the two groups. Multivariate logistic analysis revealed that age [odds ratio (OR): 1.047, 95% confidence interval (CI): 1.008-1.088, p=0.019] and hypertension (OR: 3.260, 95% CI: 1.274-8.339, p<0.014) were the independent risk factors for CKD.

Conclusion

The steatosis estimated by CAP and the fibrosis estimated by LS were not associated with the risk of CKD in patients with DM.

Conference

UEG Week Copenhagen 2023

Topics

Hepatobiliary

Submission format

Abstract

Session

PP 07 Liver & biliary (Posters)

Citation

United European Gastroenterology Journal 2023; 11 (Supplement 8)

Published

2023

More Like This:

PATHOLOGIES DISCOVERED INCIDENTALLY IN PATIENTS WITH CHRONIC VIRAL INFECTION B / D AND C DIAGNOSED IN THE SCREENING PROGRAM LIVE (RO)2 – EAST

Robert Nastasa

5-AMINOSALICYLATES FOR PATIENTS WITH ACTIVE OR QUIESCENT CROHN’S DISEASE: AN UMBRELLA REVIEW OF SYSTEMATIC REVIEWS

Yuhong Yuan

HEPATITIS C VIRUS PREVALENCE AND RISK FACTORS IN A VILLAGE FROM NORTHEASTERN ROMANIA - THE FIRST STEP TO VIRAL MICRO-ELIMINATION

Robert Nastasa

MICROBIOME MODIFICATION AND IMPROVEMENT OF SIGNS AND SYMPTOMS OF COVID-19: ILEOCOLONIC-RELEASE NICOTINAMIDE IN A PROSPECTIVE, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL

Philip Rosenstiel

OVERALL SURVIVAL AND ASSOCIATION OF PRE-CHEMOTHERAPY ALBUMIN BILIRUBIN (ALBI) PROGNOSIS SCORE IN UNRESECTABLE CHOLANGIOCARCINOMA RECEIVED SYSTEMIC CHEMOTHERAPY

Asawin Soodcharoen

NATURAL HISTORY OF ANAL STRICTURE IN PEDIATRIC-ONSET CROHN'S DISEASE: LONG-TERM FOLLOW-UP OF A POPULATION-BASED STUDY

pauline wils

UEG Poster

Standard Poster

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.